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Abstract
Background: Cyclooxygenase-2 (COX-2) plays an important role in the development of lung
cancer. DNA sequence variations in the COX-2 gene may lead to altered COX-2 production and/
or activity, and so they cause inter-individual differences in the susceptibility to lung cancer. To test
this hypothesis, we investigated the association between the 8473T>C polymorphism in the 3'-
untranslated region of the COX-2 gene and the risk of lung cancer in a Korean population.
Methods: The COX-2 genotypes were determined using PCR-based primer-introduced restriction
analysis in 582 lung cancer patients and in 582 healthy controls that were frequency-matched for
age and gender.
Results: The distribution of the COX-2 8473T>C genotypes was not significantly different between
the overall lung cancer cases and the controls. However, when the cases were categorized by the
tumor histology, the combined 8473 TC +  CC  genotype was associated with a significantly
decreased risk of adenocarcinoma as compared with the 8473 TT genotype (adjusted OR = 0.64;
95% CI = 0.46–0.90, P = 0.01). On the stratification analysis, the protective effect of the combined
8473 TC + CC genotype against adenocarcinoma was statistically significant in the males, older
individuals and ever-smokers (adjusted OR = 0.59; 95% CI = 0.39–0.91, P = 0.02; adjusted OR =
0.55; 95% CI = 0.33–0.93, P = 0.03; and adjusted OR = 0.57; 95% CI = 0.37–0.87, P = 0.01,
respectively).
Conclusion: These findings suggest that the COX-2 8473T>C polymorphism could be used as a
marker for the genetic susceptibility to adenocarcinoma of the lung.
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Background
Although cigarette smoking is the major cause of lung can-
cer, only a fraction of smokers develop lung cancer during
their lifetime, and this suggests that genetic factors are of
importance in determining an individual's susceptibility
to lung cancer [1].
Cyclooxygenase (COX, also known as prostanglandin
endoperoxide synthase) is the rate-limiting enzyme for
the production of prostaglandins (PGs) from free arachi-
donic acid. Two isoforms of COX have been identified.
COX-1 is constitutively expressed in most normal tissues
and it is considered to be a housekeeping enzyme that is
responsible for various physiologic functions. In contrast,
COX-2 is rarely expressed in normal tissues, but it is rap-
idly induced in response to cytokines, growth factors and
tumor promoters [2. 3]. Overexpression of COX-2 has
been reported in a variety of human malignancies, includ-
ing lung cancer [4-6]. Up-regulation of COX-2 can pro-
mote tumor growth and metastasis by stimulating cell
proliferation, angiogenesis, and invasiveness in addition
to inhibiting apoptosis and immune surveillance [7-10].
Moreover, a number of epidemiologic studies have
recently suggested that COX-2 inhibitor may have a pro-
tective effect on the development of lung cancer [11,12].
Taken together, these observations indicate that COX-2
plays an important role in the development of lung can-
cer. In addition, several studies have shown that the fre-
quency and level of COX-2 up-regulation was higher in
adenocarcinoma (AC) than in squamous cell carcinoma
(SCC), and small cell carcinoma (SM) showed virtually
negligible expression [6,13,14]. This suggests that the
COX-2 gene may have a pronounced association with the
development of AC.
Single nucleotide polymorphisms are the most common
form of human genetic variation, and they may contribute
to the individual susceptibility to cancer. Many studies
have demonstrated that some of these variants affect
either the expression or activities of enzymes; therefore,
they are associated with the risk of cancer [15,16]. Thus,
we hypothesized that functional SNPs in the COX-2 gene
may have an impact on COX-2 expression or activity, and
so they modulate the susceptibility to lung cancer. To test
this hypothesis, a case-control study was conducted to
evaluate the association between COX-2 polymorphisms
and the risk of lung cancer. Among the identified COX-2
polymorphisms [17-19], we have focused on the -
1186T>G and -765G>C in the promoter region and the
8473T>C  in the 3'-untranslated region (3'-UTR) since
these polymorphisms in the transcription or posttran-
scriptional regulatory regions have been reported to be
associated with various human diseases [17-21]. In the
present study, we evaluated with the association of the
8473T>C polymorphism with lung cancer because the -
1186T>G and -765G>C polymorphisms were not detected
in a preliminary study that consisted of 27 lung cancer
cases and 27 healthy controls.
Methods
Study population
This case-control study included 582 lung cancer patients
and 582 healthy controls. The details of the study popula-
tion have been described elsewhere [22-24]. In brief, the
eligible cases included all the patients who were newly
diagnosed with primary lung cancer between January
2001 and June 2002 at Kyungpook National University
Hospital, Daegu, Korea. There were no age, gender, histo-
logical or stage restrictions, but patients with a prior his-
tory of cancers were excluded from this study. The cases
included 270 (46.4%) SCCs, 205 (35.2%) ACs, 97
(16.7%) SMs, and 10 (1.7%) large cell carcinomas. The
demographics and clinical characteristics of the cases were
consistent with those of a nationwide lung cancer survey
conducted by the Korean Academy of Tuberculosis and
Respiratory Disease in 1998 [25]. The control subjects
were randomly selected from a pool of healthy volunteers
who visited the general health check-up center at Kyung-
pook National University Hospital during the same
period. The control subjects were frequency matched
(1:1) to the cancer cases based on gender and age (± 5
years). All the cases and the controls were ethnic Koreans
and they resided in Daegu City or the surrounding
regions. A detailed questionnaire was completed for each
patient and control by a trained interviewer. The question-
naire included information on the average number of cig-
arettes smoked daily and the number of years the subjects
had been smoking. For smoking status, a person who had
smoked at least once a day for > 1 year in his or her life-
time was regarded as a smoker. A former smoker was
defined as one who had stopped smoking at least 1 year
before diagnosis in the case of patients and 1 year before
the date signed on an informed consent for blood sample
collection in the case of controls. Cumulative cigarette
dose (pack-years) was calculated using the following for-
mula: pack-years = (packs per day) × (years smoked). This
study was approved by the institutional review board of
the Kyungpook National University Hospital, and written
informed consent was obtained from each participant.
COX-2 genotyping
Genomic DNA was extracted from peripheral blood lym-
phocytes by proteinase K digestion and phenol/chloro-
form extraction. The COX-2 8473T>C genotype was
determined using PCR-based primer-introduced restric-
tion analysis (PIRA) as described by Hu et al. [26]. The
PCR products were digested overnight with 10 units of
BclI (New England BioLabs, Inc., Beverly, MA, USA) at
50°C. The digested PCR products were resolved on 6%
acrylamide gel and stained with ethidium bromide for vis-BMC Cancer 2006, 6:70 http://www.biomedcentral.com/1471-2407/6/70
Page 3 of 6
(page number not for citation purposes)
ualization under UV light. To ensure quality control, the
genotyping analysis was performed "blind" with respect
to case/control status. About 10% of the samples were
randomly selected to be genotyped again by a different
author, and the results were 100% concordant. To con-
firm the genotyping results, selected PCR-amplified DNA
samples (n = 2, respectively, for each genotype) were
examined by DNA sequencing, and the results were also
100% concordant.
Statistical analysis
Cases and controls were compared using the Student's t-
test for continuous variables and the χ2 test for categorical
variables. Hardy-Weinberg equilibrium was tested with a
goodness-of-fit χ2 test with one degree of freedom for the
comparing the observed genotype frequencies with the
expected genotype frequencies among the subjects.
Unconditional logistic regression analysis was used to cal-
culate odds ratios (ORs) and 95% confidence intervals
(CIs), with adjustment for the possible confounders (gen-
der as a nominal variable; age and pack-years of smoking,
as continuous variables). Multivariate logistic regression
analyses were performed to analyze the association
between the genotypes and the risk of lung cancer after
stratification according to age (median age), gender,
smoking status, cigarette consumption (median pack-
years), and histological types of lung cancer. In case of
subgroup analysis for AC, the smoking status was catego-
rized into two groups: never-smokers and ever-smokers
(former- and current-smokers) since the number of
former smokers in the AC cases was small (n = 29). All
analyses were performed using Statistical Analysis Soft-
ware for Windows, version 8.12 (SAS institute, Gary, NC,
USA).
Results
The demographics of the cases and controls enrolled in
this study are shown in Table 1. There were no significant
differences between the cases and controls for the mean
age or gender distribution, and this suggested that the
matching based on these two variables was adequate. The
case group had a higher prevalence of current smokers
than did the controls (P < 0.001), and the number of
pack-years in the smokers was significantly higher in the
cases than in the controls (40.0 ± 17.7 versus 34.1 ± 17.8
pack-years; P < 0.001). These differences were controlled
in the later multivariate analyses.
The genotypes and polymorphic 8473C allele frequencies
of the COX-2 8473T>C polymorphism among the con-
trols and cases are shown in Table 2. The distribution of
the genotypes among the controls was in Hardy-Weinberg
equilibrium (χ = 0.35, P = 0.55). No significant deviation
was observed for the distribution of the genotypes
between the overall lung cancer cases and the controls.
However, when the cases were categorized by the tumor
histology, the distribution of the 8473T>C  genotypes
among the AC cases differed significantly from that
among the controls (P = 0.04). The distributions of the
genotypes in the SCC and SM groups were not signifi-
cantly different from that among the controls.
The lung cancer risk related to the COX-2 8473T>C geno-
types was also shown in Table 2. When the 8473 TT geno-
type was used as the reference group, the 8473 TC and the
8473 CC genotypes were associated with a non-significant
decreased risk for overall lung cancer, respectively
[adjusted odds ratio (OR) = 0.87; 95% confidence interval
(CI) = 0.68–1.11; and adjusted OR = 0.72; 95% CI = 0.41–
1.25, respectively). When the analyses were stratified by
the tumor histology, the 8473 TC genotype and the com-
bined 8473 TC + CC genotype were associated with a sig-
nificantly decreased risk of AC, respectively (adjusted OR
= 0.64; 95% CI = 0.45–0.91, P = 0.01; and adjusted OR =
0.64; 95% CI = 0.46–0.90, P = 0.01, respectively). No sig-
nificant association was found between the 8473T> C pol-
ymorphism and the risk of SCC or SM.
The association between the COX-2 8473T>C genotypes
and the risk of AC was further examined by stratifying
according to gender, age and the smoking status (Table 3).
As compared with the 8473 TT genotype, the combined
8473 TC + CC genotype was associated with a significantly
decreased risk of AC in the males and older individuals
(adjusted OR = 0.59; 95% CI = 0.39–0.91, P = 0.02; and
adjusted OR = 0.55; 95% CI = 0.33–0.93, P = 0.03, respec-
tively), whereas it had no significant effect of the risk of
AC in the females and younger individuals. When strati-
fied by the smoking status, a significant protective effect of
the combined 8473 TC + CC genotype against AC was
observed in the ever-smokers (adjusted OR = 0.57; 95%
CI = 0.37–0.87, P  = 0.01), but not in never-smokers.
When the ever-smokers were dichotomized by the median
pack-years of smoking, the protective effect of the com-
bined 8473 TC + CC genotype was similar in lighter smok-
ers and heavier smokers (data not shown).
Discussion
We investigated the influence of COX-2 polymorphisms
on the risk of lung cancer by conducting a hospital-based
case-control study. The 8473T>C polymorphism in the 3'-
UTR region of the COX-2 gene was associated with a sig-
nificantly decreased risk of AC of the lung. The protective
effects were evident in the males, the older individuals
and the smokers. These findings suggest that the COX-2
8473T>C polymorphism could be used as a marker for the
genetic susceptibility to AC of the lung. Of three major
histological types of lung cancer, the proportion of AC is
increasing world-wide. Thus, identifying the genetic fac-
tors that are responsible for the susceptibility to AC isBMC Cancer 2006, 6:70 http://www.biomedcentral.com/1471-2407/6/70
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indispensable for establishing novel and efficient ways to
prevent this disease.
Because the COX-2 -1186T>G and -765G>C  polymor-
phisms were not detected in the preliminary study that
included 27 healthy controls and 27 lung cancer cases, we
analyzed only the association of the COX-2 8473T>C pol-
ymorphism with the risk of lung cancer. The frequency of
the COX-2 8473C allele among the healthy controls in the
current study was 0.244, which was significantly lower
than that (0.535) of healthy Norwegians [18], but it was
significantly higher than that (0.187) of healthy Chinese
[26].
In the current study, the COX-2 8473T>C polymorphism
was significantly associated with the risk of AC, but it was
not associated with SCC or SM. Although the reasons for
the observed histology-specific difference in the risk con-
ferred by the COX-2 polymorphism remain to be eluci-
dated, this difference may be attributable to the
differences in the pathways of carcinogenesis among the
different histological types of lung cancer. Therefore, cer-
tain genotypes could confer a greater susceptibility to a
particular histological type of lung cancer [22-24,27,28].
Several studies have shown that the frequency and level of
COX-2 up-regulation was higher in the ACs than in the
SCCs, and the SMs showed a virtually negligible expres-
sion [6,13,14]. These observations suggest that the COX-2
gene may have a pronounced association with the devel-
opment of AC, and they are comparable with our finding
that the COX-2 polymorphism plays an important role in
determining the genetic susceptibility to AC.
A few studies have investigated the association between
the COX-2 8473T>C polymorphism and the risk of lung
cancer [18,26]. Campa et al. [18] have reported that the
8473 TC and the 8473 CC genotypes were associated with
a significantly increased risk of lung cancer in a Norwe-
gian population. In contrast to the Norwegian study, Hu
et al. [26] have reported that the combined 8473 TC + CC
genotype was associated with a significantly decreased risk
of lung cancer in a Chinese population. In concordance
with the Chinese study, the combined 8473 TC + CC gen-
otype was associated with a significantly decreased risk of
AC in our current study. Although it is hard to decipher
the reasons for the oppositely directed association of the
COX-2 8473T>C polymorphism for lung cancer in the dif-
ferent studies, several genetic and environmental factors
that are relevant to this polymorphism might have caused
the different results. Moreover, since a protective genotype
in one population may increase the cancer risk in another
population due to other linked polymorphisms that
exhibit stronger effects on the susceptibility to cancer, the
different genetic background of the study subjects should
be also considered. In addition, inadequate study design
such as nonrandom sampling, a limited sample size and
the pitfalls arising from unknown confounders should be
also considered.
Whether the COX-2 8473T>C polymorphism itself alters
mRNA stability and/or translation efficiency or if it is in
linkage disequilibrium with the other functional poly-
morphisms remains to be investigated. The 3'-UTR region
of COX-2 contains highly conserved adenosine- and urid-
ine-rich elements that are composed of the Shaw-Kamens
sequence (AUUUA), which is also known as AU rich ele-
ments [29]. This motif is present within the 3'-UTRs of
many protooncogenes and cytokine genes, and it is
involved in the regulation of COX-2 production by acting
both as a message instability determinant and a transla-
tion inhibitory element [30-32]. Therefore, the 8473T>C
polymorphism located within the functional region of 3'-
UTR of the COX-2 gene may affect the message stability
and/or translation efficiency, and so this results in differ-
ential COX-2 expression.
Several polymorphisms have been identified in the pro-
moter region of the COX-2 gene [17-19]. The -765G>C
polymorphism, which is located at just 5' to a STAT1
binding site, has been found to influence COX-2 expres-
sion and it contributes to the risk of various human dis-
eases [17,21,33]. Although the frequency of carrying the -
765 GC or CC genotype has been reported to be 25% to
50% in Caucasians [17,21,33], the -765G>C  polymor-
phism was not detected in the preliminary study that
included 27 healthy controls. These samples included 54
chromosomes, and this provides for at least a 95% confi-
dent level to detect alleles with frequencies of > 5%. Thus,
it is very likely that if this polymorphism exists, it may not
play a major role in the genetic susceptibility to lung can-
cer in the Korean population [34,35]. Kang et al. [19] have
recently reported that the -1186T>G polymorphism in the
nuclear factor kappa-B binding region was associated with
the risk of bladder cancer in a Korean population. In this
study, however, the -1186T>G  polymorphism was very
rare (the frequency of the -1186G allele was 1.0%), and
this not associated with the risk of lung cancer. In the cur-
rent study, the -1186T>G polymorphism was not detected
in the preliminary study that included 27 healthy controls
and 27 lung cancer cases, suggesting that this polymor-
phism may not play a major role in the genetic suscepti-
bility to lung cancer in the Korean population.
During multistage carcinogenesis, COX-2 can enhance
tumor invasion and metastasis [7-10]; therefore, the COX-
2 8473T>C polymorphism may have an influence on the
progression of disease. In the present study, however, no
significant difference was observed in the genotype distri-
bution according to the stage of lung cancer (data not
shown).BMC Cancer 2006, 6:70 http://www.biomedcentral.com/1471-2407/6/70
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Conclusion
We found that the 8473T>C polymorphism in the 3'-UTR
region of the COX-2 gene was associated with the risk of
lung cancer, and particularly for the risk of AC. This result
indicates that this polymorphism could be used as one
marker for defining the risk of lung cancer. However, it is
possible that our findings, particularly those findings
from stratified analyses, can be attributed to chance
because of multiple comparisons and/or the relatively
small numbers of subjects in the subgroups. Therefore,
additional studies with larger sample sizes will be
required to confirm these findings. Future studies on the
other COX-2 sequence variants and their biologic func-
tion are also needed to understand the role of the COX-2
polymorphisms in determining the risk of lung cancer.
Moreover, since genetic polymorphisms often vary signif-
icantly between the different ethnic groups, further stud-
ies are warranted to clarify the association of the COX-2
polymorphisms with the risk of lung cancer in diverse eth-
nic populations.
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